Beckman Coulter Diagnostics and Seegene Announce Supply Agreement for Multiplex Reagents for VERIS Molecular Diagnostics System

BREA, Califonia and SEOUL, Korea, Nov. 13, 2014 /PRNewswire/ --Beckman Coulter Diagnostics, a world leader in the IVD industry, and Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced a Molecular Diagnostic assay supply agreement. Under the agreement, Seegene will begin manufacturing reagents designed exclusively for Beckman Coulter's new sample-to-answer Molecular Diagnostics instrument, the VERIS MDx System*.

Logo - http://photos.prnewswire.com/prnh/20031202/BECLOGO

Richard Creager, senior vice president of the MDx Business Unit and chief scientific officer at Beckman Coulter said, "We're very excited to partner with Seegene and incorporate their novel and proprietary DPO, TOCE and MuDT technologies into our MDx solution. We expect to be able to quickly add to the menu we offer on VERIS with the Seegene Multiplex reagents that enable simultaneous and multiple detection and identification of various types of pathogens in a single test."

Seegene founder and CEO, Dr. Jong-Yoon Chun, said, "Our observation is that the VERIS system breaks new ground in enabling laboratories to perform MDx testing in the most efficient way possible. This partnership fully supports our promise to contribute to humanity by developing faster, more accurate and cost-effective innovative MDx systems."

About Seegene
As more diseases are discovered around the world, Seegene is taking the lead in developing new technology for accurate diagnosis. Seegene aims to create more opportunities for patients to start a new chapter of their lives by experiencing innovative products to increase the chance for their successful treatment. Seegene endlessly strives toward the new possibility of a world free of disease. With distributors in 57 countries and employees all around the world, Seegene strives to satisfy the varying demands of local customers by quickly listening and responding. Seegene's bold investment and endeavors in R&D allow launching numerous the world-leading products which are currently available in the market.

About Beckman Coulter
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter's instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For nearly 80 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes, offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, automation and information systems. Beckman Coulter is dedicated to advancing healthcare for every person and moving science, innovation and the lab forward. For more information, visit www.beckmancoulter.com.

*The VERIS system and VERIS human Cytomegalovirus (CMV) assay are CE cleared in Europe. The system is still in development for the United States; it is not available for in vitro diagnostic use in the United States.

Beckman Coulter, the stylized logo, and VERIS are trademarks of Beckman Coulter, Inc. and registered in the USTPO. DPO, TOCE and MuDT are trademarks of Seegene.

Contacts:	Constantine Theodoropulos
	Base Pair Group (USA)
	Phone: [phone]
	Email: [e-mail]
	Jennifer Kim
	Seegene, Inc. (Korea)
	Phone: [phone]
	Email: [e-mail]
	Mary Luthy
	Beckman Coulter Diagnostics
	Phone: [phone]
	Email: [e-mail]